Prevalence of Cyp2c9 Genetic Polymorphisms and Their Clinical Implications in Phenytoin-Treated Patients At A Regional Hospital in Indonesia
The CYP2C9*3 polymorphism is present in the Madurese population and may significantly impact phenytoin treatment response and implementing pharmacogenetic-guided therapy could improve both treatment safety and efficacy.